Neoadjuvant Sintilimab and Platinum-based Chemotherapy for Resectable Locally Advanced NSCLC Harboring no Driver Mutations: A Prospective, Randomized, Multicenter Phase III Trial
Latest Information Update: 11 May 2023
At a glance
- Drugs Sintilimab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 07 May 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2025.
- 07 May 2023 Planned primary completion date changed from 31 Oct 2022 to 31 Oct 2024.
- 22 Dec 2021 New trial record